Resources from the same session
274O - Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study
Presenter: Michael Friedlander
Session: Proffered Paper - Breast cancer, metastatic 2
Resources:
Abstract
Slides
Webcast
275O - Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)
Presenter: Volkmar Mueller
Session: Proffered Paper - Breast cancer, metastatic 2
Resources:
Abstract
Slides
Webcast
276O - Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2−) advanced breast cancer (ABC)
Presenter: Peter A. Fasching
Session: Proffered Paper - Breast cancer, metastatic 2
Resources:
Abstract
Slides
Webcast
LBA19 - GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC)
Presenter: Joan Albanell
Session: Proffered Paper - Breast cancer, metastatic 2
Resources:
Abstract
Slides
Webcast
Q&A and live discussion
Presenter: Lesley Fallowfield
Session: Proffered Paper - Breast cancer, metastatic 2
Resources:
Webcast
Invited Discussant LBA19
Presenter: Joseph Gligorov
Session: Proffered Paper - Breast cancer, metastatic 2
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Lesley Fallowfield
Session: Proffered Paper - Breast cancer, metastatic 2
Resources:
Webcast